ARIC Manuscript Proposal # 934

PC Reviewed: 04/29/03	**Status: __A__**	**Priority: __2__**
SC Reviewed: 05/05/03	**Status: ___A_**	**Priority: __2__**

1.a. Full Title: Novel risk factors and CHD prediction

b. Abbreviated Title (Length 26 characters): Novel factors & CHD ROCs

2. Writing Group (list individual with lead responsibility first):

Lead: Aaron Folsom
Address: UMN
Division of Epidemiology

Phone: 612-626-8862 Fax: 612-624-0315
E-mail: folsom@epi.umn.edu

Writing group members: Chambless, Wu, Boerwinkle, Ballantyne, Coresh, Sharrett, Heiss, Mosley, Sorlie.

3. Timeline: start summer of 2003. CSCC analysis.

4. Rationale: ARIC has produced CHD prediction models, using ROC analysis. However, these have not incorporated the novel nested case-cohort analytes.

5. Main Hypothesis/Study Questions: Does any novel marker measured in ARIC case cohort studies add to CHD prediction?

6. Data (variables, time window, source, inclusions/exclusions):

The main independent variables are selected case-cohort analytes, such as CRP, D-dimer, homocysteine, vitamin B6, sTM, ICAM, chlamydia antibody titer, etc. May include some genetic polymorphisms measured by ARIC, though none has been particularly associated with CHD previously.

Analysis will start by reproducing ARIC's previous "basic" risk model in a case-cohort subset. Then, we will test whether adding in novel markers contributes further to the ROC. In previous ARIC papers, a battery of other nontraditional risk factors contributed beyond the basic model, and these will also have to be considered. Analysis must consider that the case-cohort subset is relatively small and analytes may not completely overlap. Sample weighting needs to be incorporated.

7.a. Will the data be used for non-CVD analysis in this manuscript? ____ Yes __x__ No

b. If Yes, is the author aware that the file ICTDER02 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used? __ __ Yes ____ No
(This file ICTDER02 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? __maybe__ Yes ____ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER02 must be used to exclude those with value RES_DNA = "No use/storage DNA"? __x__ Yes ____ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status.
ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://bios.unc.edu/units/cscc/ARIC/stdy/studymem.html

___x___ Yes _____ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?
Ms 611

11. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.